INTRODUCTION
Breast cancer is the most common type of cancer in females all over the World 1 . Although the molecular etiology of breast cancer is not clearly known, hereditary genetic causes are responsible for approximately 10% 2, 3 . As with all cancers, breast cancer is a genetic disease, and many genes play a role in the molecular pathogenesis of breast cancer. Tasked with cell cycle checkpoints and DNA repair the trigger of breast cancer is the accumulation of mutations in genes withdrawn. Especially pathogenic mutations in BRCA1 and BRCA2 genes are the most critical genetic causes known for hereditary breast cancer 4, 5 . In addition to BRCA1 and BRCA2 genes, there are many genes that cause breast cancer. ATM, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 are important ones. These genes are involved in regulating homologous recombination. It also acts as tumor suppressor genes in DNA repair and is inherited as autosomal dominant or rarely autosomal recessive for example MUTYH gene. Many studies have shown that these genes are responsible for 2-5% of hereditary breast cancers 6 .
In recent years, next-generation sequencing technologies have become widespread and costeffective, making it easier to investigate mutations in both BRCA1/BRCA2 and other genes known to be responsible for breast cancer. Evaluation of hereditary breast cancer susceptibility genes in individuals enables early identification of individuals at risk and early prevention, especially the choice of preventive surgery. In addition, the importance of genetic testing in the treatment of pharmaceutical agents such as olaparib increases in recent years 7 . The National Comprehensive Cancer Network (NCCN) has published a guide on who should analyze for BRCA1/BRCA2, but there is no precise algorithm and guide for other genes yet 8 . There are not also enough studies on the frequency of mutations of genes in hereditary cancer panel in the Turkish population.
In this study, we performed hereditary cancer genetic panel test among hereditary breast cancer patients who had been performed BRCA1/BRCA2 sequence and multiplex ligation-dependent probe amplification (MLPA) analysis but no unsignificant, or pathogenic variant was detected. The frequency of mutations causing hereditary cancer among Turkish breast cancer patients other than BRCA1/2 genes was investigated.
MATERIAL AND METHODS

Patients and samples
Totaly, 70 subjects were performed at the University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Medical Genetics Clinic, between 2017 and 2019. Written informed consent was obtained from all patients before testing for the use of their DNA samples for research purposes. All the patients were unrelated and provided BRCA testing criteria according to the National Comprehensive Cancer Network (NCCN) guidelines, but they were reported as negative in both next-generation sequencing and MLPA tests. 
Variant classification
The recent ACMG/AMP guidelines for standardized variant interpretation in Mendelian disorders was used for classification. Pathogenic variants are well-established, cancer-related DNA changes in the inhouse database and/or in the literature. The main evaluation criteria are represented by robust clinical findings and family history, independent confirmatory observations, and supporting pathogenicity functional studies. Possible pathogenic variants are considered the probable cause of the disease or the effect on the protein function is predicted to be likely deleterious (>90% probability of causing the disease). Variant of uncertain significance (VUS) alterations are genetic variants with unknown or questionable impact on the condition. These variants are typically sporadic and predicted to be deleterious.
RESULTS
Of 70 patients, 6 (8.5%) were found to carry a pathogenic, and 1 (1.4%) were found to give a likely pathogenic mutation.
Pathogenic variants were detected in ATM, NBN, PTEN, RAD51C genes; the likely pathogenic variant was discovered in the MUTYH gene. Only, PTEN:c.407G>A mutation was found in two patients; the other mutations were detected once in each patient. A nonsense alteration, RAD51C:c.907G>T, was described as a novel variant, according to ClinVar, Human genome mutation database (HGMD) and current literature. VUS alteration was detected in 10 patients (14.2%).
The spectrum of pathogenic and likely pathogenic mutations comprises 4 (57.2%) nonsense variants, 3 (42.8%) missense variants. The spectrum of VUS variants comprises 7 (70%) missense variants, 1 (10%) small in-frame deletions/insertions, 1 (10%) splice site alteration, 1 (10%) start loss. All the pathogenic, likely pathogenic and VUS variants are listed in Table 2 . 
DISCUSSION
Although BRCA1/2 analysis is recommended as the first step in the diagnosis of hereditary breast cancer, BRCA1/2 mutations are identified in only 25% of patients 9 . Therefore, multiple gene panels have been optimized to identify patients who cannot be diagnosed with a molecular diagnosis. Hereditary cancer panels have also been used in routine diagnosis due to the increasing availability of next-generation sequencing technology and the reduction in costs. Although there are no radical recommendations, such as prophylactic surgery, for many of the cancer susceptibility genes other than BRCA1/2, these genes also have high protective and preventive value.
With two pathogenic and four VUS changes, the most reported gene in our study was ATM. Homozygous mutations in ATM gene cause ataxiatelangiectasia, cerebellar ataxia associated immunodeficiency syndrome 10 , while heterozygous mutations predispose to pancreatic and prostate cancer, particularly in women with breast cancer. Life-long breast cancer risk is up to 25% in women with pathogenic heterozygous ATM mutations 11 . Both pathogenic variants of ATM are a nonsense alteration. 19 .2% (180/937) of all reported disease-causing variants are nonsense alterations. ATM:c.2413C>T variation also leads to a considerable splice site alteration, was published with pancreatic ductal adenocarcinoma, in addition to breast cancer 12, 13 . ATM:c.7449G>A creates a nonsense variant, which changes a Tryptophan to a premature stop codon (TGG>TGA); however, it has been also demonstrated that ATM:c.7449G>A creates a cryptic splice donor site resulting in a deletion of the last 70 nucleotides of exon 50, previously referred to as exon 52. This variation is suggested to be a founder mutation in the Costa Rican population 14, 15 . Since there is no study on ATM founder mutations in Turkish society, it is not known whether this variant has a founder effect in the Turkish population. The only splice site alteration, ATM: c.2251-4A>G, has no significant splicing motif alteration, according to Human Splicing Finder (http://www.umd.be/HSF/). Two missense variations were reported as VUS. This variant has been published in an individual with colorectal cancer 16 . ATM Gly2287Glu was not observed at a significant allele frequency in large population cohorts. This variant is located in the FAT domain 17 . In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. One inframe deletion ATM:c.7989_7991delTGT, described as uncertain genomic alteration, previously 18 .
Although the loss of function mutations of the BRIP1 gene is mostly associated with ovarian cancer risk, the risk ratio is not reported but also increases breast cancer susceptibility 19 . Only reported variant in BRIP1 gene, BRIP1:c.3503A>C was classified as VUS. The mutated protein region is weakly conserved, and there is a moderate physicochemical difference between lysine and threonine. This variant is present in population databases (rs749589266, ExAC 0.002%). ClinVar contains two entries for this variant (Variation ID: 439028) as uncertain significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies, and their clinical significance is uncertain.
Truncating mutations in the CHEK2 gene predispose to breast cancer 20 . In our study, CHEK2 variation was reported in a single patient. Although this variation is not seen in the healthy population, it has been reported as VUS because of a change in missense and no truncating effect.
Biallelic MUTYH gene mutations predispose to breast cancer, but it is controversial that monoallelic MUYH mutations increase breast cancer 21 . In our study, only one patient had a missense likely pathogenic heterozygous MUTYH mutation (MUTYH:c.884C>T). Due to the second hit missing, the possible pathogenic change detected in this patient was not associated with the clinic.
The NBN gene, along with MRE11A and RAD50 genes, repairs the DNA damage by forming the MRN complex. Mutations of NBN gene lead Nijmegen breakage syndrome, a condition that causes slow growth in infancy and early childhood 22 . Of the three genes in the MRN complex, NBN mutation has the most substantial relationship with breast cancer 23 . Heterozygous mutations of the NBN gene may also show susceptibility to cancer 24 .
Pathogenic reported NBN variant, NBN:c.1474C>T has been previously reported pathogenically by many centers, and has a truncating effect. The results obtained from this study confirmed that heterozygous mutations of the NBN gene increased the risk of cancer.
For female PALB2 mutation carriers, the average risk of breast cancer until the age of 70 was 35% 25 . The VUS variant detected in our study, PALB2:c.833_834delTAinsAT (p.Leu278His), was identified in 2% healthy Central Asian individuals undergoing whole-genome sequencing 26 ; of note, since the genome data of the Turkish population has not been established yet, this data could not be confirmed in the Turkish people. This variant is located within a region of interaction with BRCA1 27 . In silico analysis supports that this variant does not have an impact on protein function.
PTEN mutations are diagnostic for PTEN hamartoma tumor syndrome (PHTS). There are several syndromes associated with PHTS, such as Cowden syndrome. It has been reported that lifetime risk of breast cancer increases by up to 50% in PTEN mutations 28 . Two unrelated patients had PTEN:c.407G>A mutation, in our study. This mutation has been reported pathogenic by four different reputable centers. In order to determine whether this variation has a founder effect in terms of PTEN gene mutations, it should be analyzed in larger groups. RAD51 recombinase has a critical role in the repair of DNA double-strand breaks by homologous recombination. There are five RAD51 paralogs in humans; RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3, and they promote the binding of RAD51 to the DNA 29 . Although mutations of these genes cause cancer in many tissues, they have also been reported in breast cancer. RAD51B:c.2T>C has a start loss effect because the mutation occurred at the first codon. The variant was classified as VUS since the change was not previously reported and there were no functional studies of the effect of the mutation. Although the silico database is specified as damaging for the other missense VUS variation RAD51B:c.197C>T, it has been detected at high frequency in a healthy population. Unlike these, RAD51C:c.907G>T is a nonsense variation and nonsense variants were reported as diseasecausing for this gene. Since this variant is not found in ClinVar, HGMD, cancer databases, and literature review, RAD51C:c.907G>T (p.Glu303Ter) is considered to be a novel variant. Although this mutation was found in the 7th exon of RAD51C, a 9-exon gene, RAD51C:c.955C> T in the same exon and RAD51C: c.994C> T in the 8th exon were also classified as pathogenic by HGMD.
Generally, germline mutations in the genes encoding succinate dehydrogenase (SDH) subunits result in hereditary pheochromocytomaparaganglioma syndrome, but there is also an increased risk for breast cancer 30 . Only one missense VUS variant (SDHC:c.424G>A) was described in SDH group genes. Although in silico database predicted this variant as damaging, there is no pathogenic missense variant, described with this gene.
